AstraZeneca Results Presentation Deck

Oncology: 'What's next' Solid pipeline moving forward What's next Phase I/II new medicines, selected adavosertib (WEE1¹ inhibitor) uterine, ovarian cancer oleclumab (CD73² mAb) solid tumours AZD5305 (PARP1 inhibitor) solid tumours AZD4573 (CDK9³ inhibitor) blood cancers AZD5991 (MCL14 inhibitor) blood cancers Phase I w/CTx ✓ ceralasertib (ATR5 inhibitor) solid tumours, blood cancers imaradenant (formerly AZD4635) (A2AR6 inhibitor) solid tumours MEDI5752 (PD-17/CTLA48 mAb) solid tumours AZD2811 (Aurora B inhibitor) solid tumours AZD0466 (Bcl-29/XL) blood cancers New Phase II New Phase I ✓ 1. Tyrosine kinase WEE1 2.5'-nucleotidase 3. Cyclin-dependent kinase 9 4. Induced myeloid leukaemia cell differentiation protein 5. Ataxia telangiectasia and rad3-related kinase 6. Adenosine A2A receptor 7. Programmed cell death protein 1 8. Cytotoxic T-lymphocyte-associated protein 4 9. B-cell lymphoma 2 10. Potentially pivotal Phase II. 33 What's now datopotamab deruxtecan lung cancer monalizumab head & neck cancer Orpathys NSCLC10 First approval Tagrisso NSCLC Phase III new medicines Imfinzi multiple cancers camizestrant breast cancer capivasertib breast, prostate cancer tremelimumab multiple cancers Phase III lifecycle management, major Lynparza multiple cancers New Phase III ✓ New Phase III Enhertu multiple cancers Calquence multiple cancers

View entire presentation